# EDGAR Filing Document

**Accession Number:** 0001985062
**File Stem:** 0001213900-25-097819
**Filing Date:** 2025-10
**Character Count:** 3413
**Document Hash:** ad13c5a91e19180d371189ef6e9321ac
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-097819.hdr.sgml**: 20251009

**ACCESSION NUMBER**: 0001213900-25-097819

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20251009

**FILED AS OF DATE**: 20251009

**DATE AS OF CHANGE**: 20251009

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** PSYENCE BIOMEDICAL LTD.
- **CENTRAL INDEX KEY:** 0001985062
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A6
- **FISCAL YEAR END:** 0331

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41937
- **FILM NUMBER:** 251385271

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 121 RICHMOND STREET WEST PENTHOUSE
- **STREET 2:** SUITE 1300
- **CITY:** TORONTO
- **PROVINCE COUNTRY:** A6
- **BUSINESS PHONE:** 27744604171

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 121 RICHMOND STREET WEST PENTHOUSE
- **STREET 2:** SUITE 1300
- **CITY:** TORONTO
- **PROVINCE COUNTRY:** A6

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE**

**SECURITIES EXCHANGE ACT OF 1934**

For the month of **October 2025**

Commission File Number: **001-41937**

**Psyence Biomedical Ltd.** 

(Translation of registrant's name into English)

**121 Richmond Street West<br> Penthouse Suite 1300<br> Toronto, Ontario M5H 2K1**

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

☒ Form 20-F ☐ Form 40-F

**Explanatory Note**

Psyence Biomedical Ltd (the "Company") announced that Dr. Neil Maresky has transitioned from his role as Chief Executive Officer and Director of Psyence Biomedical Ltd. to serve as the Company's Global Head, Clinical Development, where he will lead the Company's global clinical development initiatives, including its Phase 2b clinical trial in Australia.

In connection with this transition, the Company's Chairman, Mr. Jody Aufrichtig, has assumed the role of Chief Executive Officer and will oversee Nasdaq-related and corporate operations. The vacancy on the Board resulting from Dr. Maresky's transition will be filled either by way of a vote of a quorum of Directors or at the Company's next annual general meeting of shareholders, in accordance with applicable law and the Company's governing documents.

**Incorporation by Reference**

The information contained in this Report on Form 6-K is hereby incorporated by reference into the Company's Registration Statement on [Form F-3](https://www.sec.gov/Archives/edgar/data/1985062/000121390025020258/ea0231303-f3_psyence.htm) (File No. 333-285542), and any prospectuses or prospectus supplements filed pursuant thereto.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: October 9, 2025

---

| | |
|:---|:---|
| **Psyence Biomedical Ltd.** | **Psyence Biomedical Ltd.** |
| By: | /s/ Warwick Corden-Lloyd |
| Name: | Warwick Corden-Lloyd |
| Title: | Chief Financial Officer |

---